5 Key Takeaways

• 1

  Switching from dulaglutide to tirzepatide led to greater improvements in patient-reported outcomes in the SURPASS-SWITCH trial.

• 2

  Participants switching to tirzepatide reported enhanced emotional well-being and quality of life compared to those escalating dulaglutide.

• 3

  Both treatment groups showed improvements in health-related quality of life, but tirzepatide participants experienced larger gains.

• 4

  A higher proportion of patients on tirzepatide felt more hopeful and in control of their diabetes compared to those on dulaglutide.

• 5

  The study indicates that tirzepatide may offer benefits beyond glycemic control, including emotional and functional improvements.